Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

ARA-290 Nasal Spray

£26.24£47.48

Buy ARA-290 Nasal Spray

ARA-290 is a version of erythropoietin that reduces inflammatory pathways through paracrine signalling and natural repair receptors. Studies show that ARA-290 lowers HbA1c, improves cholesterol, controls neuropathic pain and peripheral neuropathies, and speeds up the healing of wounds.

ARA290 15ml contains: 2mg
ARA290 30ml contains: 4mg

Buy 10 and get 10% Discount

473 in stock

Description

ARA-290 Nasal Peptide Spray Australia

This product is intended for research purposes only. To be used by trained professionals only.

ARA-290 is a non-erythropoietic peptide derived from erythropoietin that has shown promise in treating a wide range of conditions. ARA-290 works by activating the innate repair receptor, which is a heteromer of the erythropoietin receptor and β-common receptor. By activating this receptor, studies have demonstrated that ARA-290 nasal spray could help to promote tissue repair and regeneration, reduce inflammation, and improve overall health and wellbeing.

One of the most well-studied applications of ARA-290 nasal spray is in the treatment of neuropathic pain. Several Australia studies have shown that ARA-290 can provide long-term relief of neuropathic pain, with minimal side effects. ARA-290 may work by suppressing spinal microglia, reducing inflammation, and promoting tissue repair in the affected areas [1].

ARA-290 has also shown promise in the treatment of type 2 diabetes. One Australia study found that ARA-290 improved metabolic control and neuropathic symptoms in patients with type 2 diabetes. This may be due to the peptide’s ability to improve blood flow and oxygenation to damaged tissues and promote tissue repair and regeneration [2].

Other areas of research have looked at the potential benefits of ARA-290 in treating sarcoidosis, autoimmune diseases, and other conditions. ARA-290 has been shown to improve small fibre neuropathy in sarcoidosis patients, reduce inflammation and tissue damage in experimental autoimmune neuritis, and protect against systemic lupus erythematosus [3].


References:

[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3883966/

[2] https://www.researchgate.net/ publication/268230288_ARA_290_ a_Nonerythropoietic_Peptide_ Engineered_from_Erythropoietin_ Improves_Metabolic_Control_ and_Neuropathic_Symptoms_in_ Patients_with_Type_2_Diabetes

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC6010693/


Molecular Formula: C51H84N16O21
Sequence: XEQLERALNSS

Research use only. Not for human or animal consumption!

ARA-290 HPLC 2023 Certificates_DIRECT PEPTIDES

 

 

 

 

 

 

 

 


ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Australia Direct Peptides website: https://australia.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.


BUY ARA-290 Nasal Spray ONLINE today From Australia Direct Peptides